RENBP and cancer: KEGG enrichment analysis (p < 0.05) showed that the targets mainly had significant effects on 105 signaling pathways such as proteoglycans in cancer (hsa05205), hepatitis B (hsa05161), endocrine resistance (hsa01522), AGE-RAGE signaling pathway in diabetic complications (hsa04933), Epstein–Barr virus infection (hsa05169) and p53 signaling pathway (hsa04115) (Figure 3E).